Clinical trials: Neoplasm, Oral
Oral Mucositis
Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation
The main purpose of this study is to assess the efficacy of melatonin oral gel compared to placebo in the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing concurrent chemoradiation.
- Trial name
- MUCOMEL (NCT02630004)
- Testing
- Melatonin oral gel 3%
- Where
- 11 sites in Spain
- Volunteers
- 84 people
- Sponsor
- Spherium Biomed
Solid Tumours
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
To determined what dose of topotecan can be safely given with daily pazopanib.
- Trial name
- NCT00732420
- Testing
- topotecan, pazopanib
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021…
- Trial name
- NCT01677780
- Testing
- RO5045337
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00003327
- Testing
- paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theradex
Non-Small Cell Lung Cancer
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
- Trial name
- TARGET-D 202 (NCT07659782)
- Testing
- VS-7375
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 105 people
- Sponsor
- Verastem, Inc.
Solid Tumour
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid…
- Trial name
- NCT01300468
- Testing
- PHA-848125AC
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Nerviano Medical Sciences
Neoplasms by Site, Lymphoma, Non-hodgkin
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer.
- Conditions
- Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT00562224
- Testing
- PCI-24781
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pharmacyclics LLC.
Carcinoma, Non-Small-Cell Lung
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent…
- Trial name
- NCT00806819
- Testing
- Nintedanib (BIBF1120), Pemetrexed, B12
- Where
- 163 sites in United States, Argentina and 30 more
- Volunteers
- 718 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.).
- Trial name
- NCT05266105
- Testing
- Palazestrant, Palbociclib
- Where
- 8 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
- Trial name
- TARGET-D 203 (NCT07659795)
- Testing
- VS-7375, cetuximab, panitumumab
- Where
- 30 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Verastem, Inc.
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Solid Tumors
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and…
- Trial name
- NCT02279433
- Testing
- DS6051b
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Nuvation Bio Inc.
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Investigation of maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992
- Trial name
- NCT02171728
- Testing
- BIBW 2992
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor
BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects
An open-label, randomized, single-dose, 2-way crossover study to compare the bioavailability of two IMP4297 formulations (20 mg capsules and 10 mg capsules) after single oral administration of 100 mg IMP4297 under fasted…
- Trial name
- NCT04351165
- Testing
- IMP4297
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.
Solid Tumors, Breast Cancer
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
This is a phase I/II clinical research study with BGT226, an inhibitor of phosphatidylinositol 3'-kinase (PI3K). The study consists of a Phase I dose escalation part followed by a safety expansion part and a Phase II expansion…
- Conditions
- Solid Tumors, Breast Cancer, Cowden Syndrome
- Trial name
- NCT00600275
- Testing
- BGT226
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Acute Myelogenous Leukemia (AML)
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
The main purpose of this study are to determine the maximum dose of AT-406 that can be safely given in combination with cytarabine and daunorubicin to humans.
- Trial name
- NCT01265199
- Testing
- AT-406 in combination with daunorubicin and cytarabine
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Ascenta Therapeutics
Non Small Cell Lung Cancer, Cancer
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.
- Trial name
- NCT04274907
- Testing
- Venetoclax, Pembrolizumab
- Where
- 39 sites in United States
- Volunteers
- 2 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.